You are viewing the site in preview mode
Skip to main content
|
Variables
|
Outcome by Program
|
|---|
|
UTT (N, %)
|
CD4 based (N, %)
|
Total
|
|---|
|
TB
|
NO TB
|
TB
|
NO TB
|
(N, %)
|
|---|
|
WHO stage
|
|
Stage I
|
0 (0)
|
38 (31.1)
|
3 (9.1)
|
48 (21.5)
|
89 (23.1)
|
|
Stage II
|
1 (16.7)
|
38 (31.1)
|
5 (15.3)
|
53 (23.8)
|
97 (25.2)
|
|
Stage III
|
3 (50)
|
40 (32.8)
|
22 (66.7)
|
115 (51.5)
|
180 (47)
|
|
Stage IV
|
2 (33.3)
|
6 (4.9)
|
3 (9)
|
7 (3.2)
|
18 (4.7)
|
|
Median CD4 count
|
262.4 (IQR: 130–568)
|
181 (IQR: 110–235)
|
201 (IQR: 126–303)
|
|
Mean weight
|
52.5+ 2
|
51 + 9
|
52.3+ 11.3
|
|
Median time to Rx
|
0.3 (IQR = 0.1–4.2)
|
0.9 (IQR = 0.6–1.6)
|
0.7 (IQR = 0.2–1.2)
|
|
OIS before ART
|
|
Yes
|
3 (50)
|
49 (40.2)
|
22 (66.7)
|
116 (52)
|
190 (49.5)
|
|
No
|
3 (50)
|
73 (59.8)
|
11 (33.3)
|
107 (48)
|
194 (50.5)
|
|
IPT
|
|
Yes
|
4 (66.7)
|
113 (92.6)
|
11 (33.3)
|
155 (69.5)
|
283 (73.7)
|
|
No
|
2 (33.3)
|
9 (7.4)
|
22 (66.7)
|
68 (30.5)
|
101 (26.3)
|
|
Treatment failure
|
|
Yes
|
3 (50)
|
9 (7.4)
|
2 (6)
|
6 (2.7)
|
20 (5.2)
|
|
No
|
3 (50)
|
113 (92.6)
|
31 (94)
|
217 (97.3)
|
364 (94.8)
|
- IPT Isoniazid preventive therapy, RX Treatment
